Epigenetic therapy to sensitize patients with advanced NSCLC to chemotherapy and immunotherapy targeting reversal of immune tolerance

Grant Details

Grantee Name: Stephen Baylin and Julie Brahmer
Organization: John Hopkins University
Country: United States

Focus Area: Therapy Optimization
Funding Year: 2014
Funding Scheme: RTFCCR open call
Project period: 4 years

The team had found in an earlier study that epigenetic therapy appears to sensitize patients to subsequent treatments including chemotherapy, and very excitingly, to immunotherapy, targeting reversal of immune tolerance. 

Two new clinical trials will investigate an approach to reverse gene silencing associated with increased tumor growth using DNA methyltransferase inhibitor (azacitidine) and histone deacetylase inhibitor (entinostat). The first clinical trial will investigate the proposed therapy to address chemoresistance and the second trial will sensitize patients for immunotherapies. If validated, the study could in a delimited time span, introduce new therapies to radically alter the management of cancers like NSCLC.

icon-social-share-linkedin Created with Sketch.
icon-play Created with Sketch.
icon-download Created with Sketch.